Lyell Immunopharma, Inc. · NASDAQ:LYEL
Lyell Immunopharma, Inc. shareholders
As of Jun 30, 2026, 83 institutions reported holding Lyell Immunopharma, Inc., 48.9% of its shares. Largest: ARCH Venture Management, LLC, GSK plc and Vanguard. New holders, exits, insiders and big stakes, each with its filing.
| Holder | Shares | % of Lyell Immunopharma, Inc. | Change | Filed |
|---|---|---|---|---|
| ARCH Venture Management, LLC | 3.25M | 13.3% | no change | Aug 14, 2026 |
| GSK plc | 1.51M | 6.2% | no change | Aug 13, 2026 |
| Vanguard | 977K | 4.0% | +144K | Aug 13, 2026 |
| Orland Properties Ltd | 755K | 3.1% | no change | Aug 5, 2026 |
| BlackRock | 724K | 3.0% | +533K | Aug 7, 2026 |
| Almitas Capital LLC | 581K | 2.4% | +3,600 | Aug 17, 2026 |
| Foresite Capital Management V, LLC | 476K | 1.9% | −692 | Aug 14, 2026 |
| Millennium | 367K | 1.5% | −91,432 | Aug 14, 2026 |
| Opaleye Management Inc. | 344K | 1.4% | +265K | Aug 14, 2026 |
| venBio Partners LLC | 338K | 1.4% | no change | Aug 14, 2026 |